Orion Oyj

HEL:ORN1V ISIN:FI0009800320

 
 

News

Orion Oyj (HEL:ORN1V) Orion Comments On ANDA Filed By Wockhardt Limited For A Generic Version Of Orion's Proprietary Drug Stalevo® In The United States

🕔11/3/2008 4:33:02 PM 2025

Orion Oyj (HEL:ORN1V) Company states the realisation of generic competition is still neither certain nor imminent

Read Full Article

Orion Oyj (HEL:ORN1V) Composition Of The Nomination Committee Of Orion Corporation

🕔10/30/2008 1:51:00 AM 1698

Orion Oyj (HEL:ORN1V) The Board of Directors of Orion Corporation has elected the following persons to the Nomination Committee of the company: Kari Jussi Aho Matti Kavetvuo Timo Maasilta Timo Ritakallio Jukka Ylppö.

Read Full Article

Orion Oyj (HEL:ORN1V) Orion Group Interim Report 1-9/2008

🕔10/28/2008 9:19:00 PM 3837

Orion Oyj (HEL:ORN1V) Orion's net sales in January-September 2008 stood at EUR 530.1 million (1-9/2007: EUR 509.6 million), up by 4.0% on the comparative period of January-September 2007.

Read Full Article

Orion Oyj (HEL:ORN1V) Orion Corporation's Publication Schedules For Financial Reporting In 2009

🕔10/28/2008 9:15:00 PM 1285

Orion Oyj (HEL:ORN1V) Orion Corporation will publish its financial result for 2008 on Friday, 6 February 2009.

Read Full Article

Orion Oyj (HEL:ORN1V) Orion Publishes Interim Report 1-9/2008 On 28 Oct 2008

🕔10/17/2008 3:33:00 PM 1287

Orion Oyj (HEL:ORN1V) Orion Corporation will publish its Interim Report for the period of January-September 2008 on Tuesday 28 October 2008 at 8:30 EET. The release and the presentation material will be available after publication on the Group's homepage at www.orion.fi/investors.

Read Full Article

Orion Oyj (HEL:ORN1V) Orion Comments On New ANDA By Sun Pharma Global, Inc. For Generic Entacapone (Orion's Proprietary Drug Comtan®) In The United States

🕔10/8/2008 2:15:00 AM 1269

Orion Oyj (HEL:ORN1V) Company states the realisation of generic competition is still neither certain nor imminent

Read Full Article

Orion Oyj (HEL:ORN1V) Orion Updates Progress With Dexmedetomidine Trials

🕔9/12/2008 7:37:00 PM 1039

Orion Oyj (HEL:ORN1V) With this release, Orion Corporation updates information provided earlier on the Phase III clinical studies which are under way with dexmedetomidine, a sedative for patients in intensive care, with an aim to have the product registered in Europe as a long-term infusion, administered for over 24 hours. In these studies, the efficacy and safety of dexmedetomidine is compared with sedatives currently used in intensive care, i.e. midazolam in the MIDEX study and propofol in the PRODEX study, altogether in approximately 1,000 patients.

Read Full Article

Orion Group Interim Report 1-6/2008

🕔8/5/2008 7:27:38 PM 1167

Orion Oyj Steady growth continued

Read Full Article

500,000 Orion A-shares Converted Into B-shares

🕔7/28/2008 5:33:00 PM 761

Orion Oyj In accordance with Section 3 of the Articles of Association of Orion Corporation, 500,000 A-shares have been converted into 500,000 B-shares. The conversion has been entered into the Trade Register on 28 July 2008. After the conversion there are 51,440,668 A-shares and 89,817,160 B-shares in the company.

Read Full Article

Orion Corporation Publishes Interim Report Q2/2008 On 5 August 2008

🕔7/23/2008 5:01:00 PM 950

Orion Oyj Orion Corporation will publish its Interim Report for the period of January-June 2008 on Tuesday, 5 August 2008. The estimated time of disclosure is 12.00 Finnish time. The release and the presentation material will be available after publishing on the Group's homepage at www.orion.fi/investors.

Read Full Article
###

2,938 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 4) (Last 30 Days: 16) (Since Published: 2938) 

Company Data